New on this website

13.11.2026

HPC – Credelio ad us. vet., Kautabletten für Katzen

Sehr seltene Fälle von Krampfanfällen bei Katzen

12.11.2026

Extended deadline for publishing officially mandated information materials on the electronic publication platform

Swissmedic has noted that the obligation to publish officially mandated information materials has not been fully implemented. Publications that are still outstanding must be submitted by 31 December 2026

12.11.2026

Vaccinovigilance - Annual report 2025

Summary of adverse events following immunization reported in Switzerland during 2025

10.11.2026

Designer drugs: FDHA brings further psychoactive substances under control

New synthetic drugs can harbour considerable health risks

10.11.2026

Batch recalls – Ologynelle, Filmtabletten

Rückzug der Chargen 260513 und 260514 bis auf Stufe Detailhandel

09.11.2026

Publication eCTD v4.0 Implementation Guide Package v2.0

Swissmedic has published version 2.0 of the eCTD v4.0 Implementation Guide Package

09.11.2026

NAD+ supplements: When lifestyle products have criminal consequences

Health trends in the conflict between marketing and regulation

05.11.2026

Swissmedic Journal

Latest edition
Swissmedic Journal October 2026

04.11.2026

Save the Date: Clinical Trials Symposium 2027

The Clinical Trials Symposium returns with a fresh format, uniting experts from healthcare institutions, academia and industry

04.11.2026

DHPC – Respreeza (alpha-1-proteinasi inhibitor humanum)

Defekte der Verschlussintegrität mit Risiko einer Dosisversäumnis und potenziellen Infektion

03.11.2026

Swissmedic Vigilance News Edition 37

We are publishing original articles in English as well as a summary of each in all four languages

03.11.2026

Vigilance for veterinary medicinal products - Annual report 2025

Summary of adverse reactions reported in Switzerland in 2025

03.11.2026

Wichtige Information von Swissmedic

Behördlich angeordnetes Informationsmaterial ist ab sofort einfach und zentral über www.swissmedicinfo-pro.ch abrufbar

02.11.2026

Update of publications on parenteral products without a medical purpose

Swissmedic has updated the position paper “Parenterals without an intended medical purpose – Enforcement at product level ” and the “Information sheet for the cosmetic sector – Parenterals without an intended medical Purpose”. The updates concern clarifications in the wording and do not affect the current enforcement practice. The updated versions are now available for download

02.11.2026

Eye disorders during amiodarone treatment

Learning from adverse reaction reports – cases from pharmacovigilance

02.11.2026

Out-of-Stock – Duvaxyn WNV ad us. vet., Injektionsemulsion für Pferde

Befristete Bewilligung zum Vertrieb in spanischer Aufmachung

02.11.2026

Submission of notifications of major changes via the Swissmedic Portal from 1 November 2026

From 1 November 2026, notifications of major changes must be submitted exclusively via the Swissmedic Portal (SMC Portal)

02.11.2026

Additional information on the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”

Additional labels on primary packaging are not permitted for parallel imported human medicinal products. Medicinal products that have already been authorised have a transitional period of one year to apply for the required changes

01.11.2026

Modification of the “Form DMF”

Encrypted e-mail delivery to DMF holder via IncaMail

01.11.2026

Update to the forms New authorisation of human medicinal products and Variations and extensions HAM

Due to changes to the medicinal products categories and the central publication of officially mandated information material by conformation, an update to the forms New authorisation of human medicinal products and Variations and extensions HAM is necessary

26.10.2026

Out-of-Stock – Cablivi 10 mg, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

Befristete Bewilligung zum Vertrieb in deutscher Aufmachung

20.10.2026

New strategic approach to minimizing animal testing in the development of medicinal products

Swissmedic consistently supports the international 3Rs strategy

16.10.2026

Die neue Pharmacopoea Helvetica 13

Die neue Pharmacopoea Helvetica ist publiziert. Der Institutsrat hat beschlossen, die 13. Ausgabe der Schweizerischen Pharmakopöe auf den 1. April 2027 in Kraft zu setzen.

13.10.2026

Haemovigilance Annual report 2025

Evaluation of haemovigilance reports in 2025

12.10.2026

Neuroleptic malignant syndrome associated with antipsychotic treatment

Learning from adverse reaction reports – cases from pharmacovigilance

12.10.2026

Out-of-Stock – Syntocinon Nasenspray, Lösung; Oxytocin 40 I.E./ml

Befristete Bewilligung zum Vertrieb in norwegischer/schwedischer Aufmachung

09.10.2026

GMP compliance by foreign manufacturers

Simplifications for industry and clarification of unresolved issues

01.10.2026

Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”

Swissmedic has updated the Guidance document on parallel imports. In particular, the changes concern clarifications on country of export, additions to the requirements for packaging, storage instructions and information on handling in the medicinal product information for parallel imported medicinal products

01.10.2026

Revision of the Guidance document Authorisation Biosimilar

Following finalisation of the EMA Reflection paper on a tailored clinical approach in biosimilar development, the Guidance document Authorisation Biosimilar has been adapted accordingly

01.10.2026

Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances

As of 15 November 2026, the prior registration of active substances in the EMA SMS database (Substances Management Services) will become a mandatory requirement for their inclusion in establishment licences and GMP certificates

29.09.2026

HPC - Librela ad us. vet., Injektionslösung für Hunde (Bedinvetmabum)

Neue Vorsichtsmassnahmen für die Anwendung bei Tieren und neue Nebenwirkungen

26.09.2026

DHPC – Clozapin

Überarbeitete Empfehlungen für die routinemässige Kontrolle des Blutbildes im Hinblick auf das Risiko einer Agranulozytose

25.09.2026

DHPC – Remsima® (Infliximab)

Die neue intravenöse Formulierung (100 mg und 350 mg, Konzentrat zur Herstellung einer Infusionslösung) enthält Sorbitol und ist daher bei Patientinnen und Patienten mit hereditärer Fruktoseintoleranz (HFI) kontraindiziert

25.09.2026

Out-of-Stock – Ketazed, Augentropfen-Lösung

Befristete Bewilligung zum Vertrieb in schwedischer / finnischer Aufmachung

24.09.2026

Swissmedic Portal Release Notes – 23.09.2026

In the release on September 23rd, we enable the viewing of specialist data for complementary medicines in the notification procedure (Chapter 7 KPTPO; basic company dossier, master dossier and medicines (single notifications)) for marketing authorisation holders.
Furthermore, the submission of major changes in accordance with Article 41(2) of the AMBV has been introduced for establishment licence holders.

24.09.2026

Information on the Swissmedic Portal release – 23 September 2026

Specialist data for complementary medicines in the notification procedure (Chapter 7 KPTPO) in the Swissmedic Portal for marketing authorisation holders

24.09.2026

Swissmedic Portal Release – New Features Available from 23 September 2026

Submission of major changes (establishment licences) and viewing of specialist data for complementary medicines in the notification procedure

23.09.2026

I-SMI.TI.22e Notifications according to Article 41, MPLO

Swissmedic has published a new version of the document

21.09.2026

DHPC – Apremilast Leman (apremilastum)

Fehler beim Verfallsdatum

18.09.2026

Batch recall – Elocom, Lösung zur Anwendung auf der Haut

Rückzug der Charge C135341 bis auf Stufe Detailhandel
Permanent link of this page
www.swissmedic.ch/updates-en
News channel of this page

Last modification 01.02.2026

Top of page